Updating results

1301 results

Sort: Relevance | Date

Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)

This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

NICE guideline Published August 2015

Developing and updating local formularies (MPG1)

This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

Medicines practice guideline Published March 2014 Last updated October 2015

Patient group directions (MPG2)

This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

Medicines practice guideline Published August 2013 Last updated March 2017

Managing medicines for adults receiving social care in the community (NG67)

This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

NICE guideline Published March 2017

Controlled drugs: safe use and management (NG46)

This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

NICE guideline Published April 2016

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene..

Highly specialised technologies guidance Published July 2016

Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa (MPS IVA)

Highly specialised technologies guidance Published December 2015

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Evidence-based recommendations on culizumab (Soliris) for treating atypical haemolytic uraemic syndrome (aHUS)

Highly specialised technologies guidance Published January 2015

Migalastat for treating Fabry disease (HST4)

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Highly specialised technologies guidance Published February 2017

Eliglustat for treating type 1 Gaucher disease (HST5)

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Highly specialised technologies guidance Published June 2017

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Highly specialised technologies guidance Published October 2018

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Highly specialised technologies guidance Published August 2017

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID)

Highly specialised technologies guidance Published February 2018

Inotersen for treating hereditary transthyretin amyloidosis (HST9)

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Highly specialised technologies guidance Published May 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)

Highly specialised technologies guidance Published October 2019

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: TBC

Highly specialised technologies guidance In development

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 08 September 2020

Highly specialised technologies guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: 03 June 2020

Highly specialised technologies guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 [ID943]

In development [GID-HST10008] Expected publication date: 27 November 2019

Highly specialised technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Highly specialised technologies guidance In development

OTL-200 for treating metachromatic leukodystrophy [ID1666]

Proposed [GID-HST10028] Expected publication date: TBC

Highly specialised technologies guidance Proposed

CardioQ-ODM oesophageal doppler monitor (MTG3)

Evidence-based recommendations on the CardioQ-ODM oesophageal doppler monitor for people having major or high-risk surgery

Medical technologies guidance Published March 2011

Mega Soft Patient Return Electrode for use during monopolar electrosurgery (MTG11)

Evidence-based recommendations on the Mega Soft Patient Return Electrode for use during monopolar electrosurgery

Medical technologies guidance Published August 2012

MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)

Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery

Medical technologies guidance Published November 2011 Last updated February 2018

EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing

Medical technologies guidance Published January 2013 Last updated October 2019

Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (MTG10)

Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms

Medical technologies guidance Published May 2012 Last updated January 2019

Ambu aScope4 Broncho for use in unexpected difficult airways (MTG14)

Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways

Medical technologies guidance Published July 2013 Last updated June 2019

The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

Evidence-based recommendations on the MAGEC system for spinal lengthening in children with scoliosis (curvature of the spine)

Medical technologies guidance Published June 2014

WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation (AF) when diagnosing and managing hypertension

Medical technologies guidance Published January 2013

SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)

Evidence-based recommendations on SeQuent Please balloon catheter for in-stent coronary restenosis

Medical technologies guidance Published December 2010

VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (nerve damage)

Medical technologies guidance Published December 2014 Last updated March 2015

XprESS multi sinus dilation system for treating chronic sinusitis (MTG30)

Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed

Medical technologies guidance Published December 2016

The TURis system for transurethral resection of the prostate (MTG23)

Evidence-based recommendations on the transurethral resection in saline system (TURis) for resection of the prostate

Medical technologies guidance Published February 2015

Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

Evidence-based recommendations on the Parafricta Bootees and Undergarments to reduce the development or risk of pressure ulcers caused by skin breakdown

Medical technologies guidance Published November 2014

moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

Evidence-based recommendations on the moorLDI2-BI a laser doppler blood flow imager for burn wound assessment

Medical technologies guidance Published March 2011 Last updated August 2017

The geko device for reducing the risk of venous thromboembolism (MTG19)

Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism (VTE)

Medical technologies guidance Published June 2014

The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)

Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds

Medical technologies guidance Published March 2014 Last updated March 2019

HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (MTG32)

Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography

Medical technologies guidance Published February 2017

HumiGard for preventing inadvertent perioperative hypothermia (MTG31)

Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery

Medical technologies guidance Published February 2017

GreenLight XPS for treating benign prostatic hyperplasia (MTG29)

Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia (BPH)

Medical technologies guidance Published June 2016

Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease (MTG28)

Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in patients with sickle cell disease

Medical technologies guidance Published March 2016